Furthermore, lncRNA DLEU1 deletion could promote TMZ sensitivity to glioma cells via enhancing apoptosis and regulating autophagy, which enriched the mechanism of temozolomide sensitivity and provided a potential biomarker for the individualized use of temozolomide in glioma. The gene discussed is DLEU1; the disease is glioma.